Avacopan added to standard care for kidney vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy (a small sample of kidney tissue) either done recently or be willing to have one done early in the study.
- You must be newly diagnosed or have a flare of a type of vasculitis affecting the kidneys (called GPA or MPA).
- Your kidney function must be very low (estimated GFR between 0 and 29) and you need to have blood or protein in your urine.
- You must be planning to start or have recently started standard treatment for this flare with medications like rituximab or cyclophosphamide plus steroids.
- You must not have severe liver problems, active infections, certain other autoimmune diseases, or a history of cancer in the last 3 years.
- If you are a woman who can have children, you must use effective birth control during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This study brings together patients with ANCA-associated vasculitis (AAV) and their doctors to talk about how they make treatment decisions together. The goal is to understand what matters to patients so care can be more collaborative.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
Hear when a new ANCA-Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.